Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 400-412

  Hess, Stephen D ^a   Egilmez, Nejat K ^a   Bailey, Nicola ^b   Anderson, Timothy M ^c   Mathiowitz, Edith ^b   Bernstein, Steven H ^d   Bankert, Richard B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BROWN UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; GAMMA INTERFERON; MICROSPHERE; NEUTRALIZING ANTIBODY; NITRIC OXIDE SYNTHASE; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY CELL; LUNG TUMOR; LYMPHOCYTE MIGRATION; MALE; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 0037220470     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.400     Document Type: Article

References (64)

1. Van Waes, C., J. L. Urban, J. L. Rothstein, P. L. Ward, and H. Schreiber. 1986. Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. J. Exp. Med. 164:1547.
2. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
3. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe. E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
4. Fernandez-Cruz, E., B. A. Woda, and J. D. Feldman. 1980. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J. Exp. Med. 152:823.
5. - lymphocytes. J. Exp. Med. 154:952.
6. + idiotype-specific T cell. J. Immunol. 142:409.
7. - T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J. Immunol. 133:1671.
8. - T cells: Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122.
9. Monach, P. A., S. C. Meredith, C. T. Siegel, and H. Schreiber. 1995. A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45.
10. + MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J. Immunol. 154:4613.
11. + T-cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96:8633.
12. + T-cells in the antitumor immune response. J. Exp. Med. 188:2357.
13. Levitsky, H. I., A. Lazenby, R. J. Hayashi, and D. M. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J. Exp. Med. 179:1213.
14. + effector T-cells mediate an indirect IL-12 and IFN-γ-dependent suppression of autologous lung tumor xenografts in SCID mice. Cancer Res. 62:2611.
15. Bankert, R. B., N. K. Egilmez, and S. D. Hess. 2001. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22:386.
16. Sugiyama, Y., M. Kato, F.-A. Chen, S. S. Williams, Y. Kawaguchi, K. Miya, Y. S. Jong, E. Mathiowitz, N. K. Egilmez, and R. B. Bankert. 2001. Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J. Immunother. 24:37.
17. Tanaka, T., M. Tsudo, H. Karasuyama, F. Kitamura, T. Kono, M. Hatakeyama, T. Taniguchi, and M. Miyasaka. 1991. A novel monoclonal antibody against murine IL-2 receptor β-chain: Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J. Immunol. 147:2222.
18. Mathiowitz, E., J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chickering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S. Montgomery, M. Bassett, and C. Morrell. 1997. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410.
19. Iwanuma, Y., F.-A. Chen, N. K. Egilmez, H. Takita, and R. B. Bankert. 1997. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 57:2937.
20. Hess, S. D., N. K. Egilmez, J. Shiroko, and R. B. Bankert. 2001. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Ther 8:371.
21. Trinchieri, G., M. Matsumoto-Kobayashi, S. C. Clark, J. Sechra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160:1147.
22. Bloor, A. G., Y.-H. Jou, C. Hoeplinger, J. E. Gartner, G. L. Mayers, and R. B. Bankert. 1982. Hapten-specific, B cell repertoire probed by hybridoma technology: Selection and characterization of representative clonotypes from the antibody-forming cell pool. J. Immunol. 128:1443.
23. Koblish, H. K., C. A. Hunter, M. Wysocka, G. Trinchieri, and W. M. F. Lee. 1998. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188:1603.
24. Jensen, G. S., S. Poppema, M. J. Mant, and L. M. Pilarski. 1989. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int. Immunol. 1:229.
25. Schoenhaut, D. S., A. O. Chua, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, W. McComas, P. C. Familletti, M. K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433.
26. Desai, B. B., P. M. Quinn, A. G. Wolitzky, P. K. A. Mongini, R. Chizzonite, and M. K. Gately. 1992. The IL-12 receptor II: Distribution and regulation of receptor expression. J. Immunol. 148:3125.
27. Trinchieri, G. 1994. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
28. Trinchieri, G. 1998. Immunobiology of interleukin-12. Immunol. Res. 17:269.
29. Radrizzani, M., P. Accornero, A. Amidei, A. Aiello, D. Delia, R. Kurrle, and M. P. Colombo. 1995. IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation. Cell. Immunol. 161:14.
30. Pirtskhalaishvili, G., G. V. Shurin, C. Esche, Q. Cai, R. R. Salup, S. N. Bykovskaia, M. T. Lotze, and M. R. Shurin. 2000. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J. Cancer 83:506.
31. Williams, S. S., F.-A. Chen, H. Kida, S. Yokota, K. Miya, M. Kato, M. P. Barcos, H. Wang, T. Alosco, T. Umemoto, et al. 1996. Engraftment of human tumorinfiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol. 156:1908.
32. Egilmez, N. K., Y. S. Jong, M. S. Sabel, J. S. Jacob. E. Mathiowitz, and R. B. Bankert. 2000. In situ vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent anti-tumor immunity. Cancer Res. 60:3832.
33. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
34. Le, H. N., N. C. Lee, K. Tsung, and J. A. Norton. 2001. Pre-existing tumorsensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol. 167:6765.
35. Radrizzani, M., P. Accornero, A. Amidei, A. Aiello, D. Delia, R. Kurrle, and M. P. Colombo. 1995. IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation. Cell. Immunol. 161:14.
36. Pirtskhalaishvili, G., G. V. Shurin, C. Esche, Q. Cai, R. R. Salup, S. N. Bykovskaia, M. T. Lotze, and M. R. Shurin. 2000. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J. Cancer 83:506.
37. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
38. Leist, T. P., M. Eppler, and R. M. Zinkernagel. 1989. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-γ interferontreated mice. J. Virol. 63:2813.
39. + T cells is dependent on interferon-γ. Lymphokine Cytokine Res. 10:353.
40. Campbell, I. L., T. W. H. Kay, L. Oxbrow, and L. C. Harrison. 1991. Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87:739.
41. Debray-Sachs, M., C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J.-F. Bach. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN-γ. J. Autoimmun. 4:237.
42. Belosevic, M., D. S. Finbloom, P. H. Van der Meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
43. Cox, G. W., G. Melillo, U. Chattopadhyay, D. Mullet, R. H. Fertel, and L. Versio. 1992. Tumor necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol. 149:3290.
44. Belosevic, M., D. S. Finbloom, M. S. Meltzer, and C. A. Nacy. 1990. A cofactor for induction of activated macrophage resistance to infection. J. Immunol. 145:831.
45. Stout, R. D., and K. Bottomly. 1989. Antigen-specific activation of effector macrophages by IFN-γ producing (Th1) T cell clones: Failure of IL-4-producing (Th2) T cell clones to activate effector function in macrophages. J. Immunol. 142:760.
46. Wigginton, J. M., D. B. Kuhns, T. C. Back, M. J. Brunda, R. H. Wiltrout, and G. W. Cox. 1996. Interleukin-12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: Implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131.
47. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick, J. Kasper, J. Dzuiba, J. Van Damme, A. Walx, and D. Marriott. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270:27348.
48. Sgadari, C., A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, et al. 1996. Interferoninducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93:13791.
49. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 89:2635.
50. Strieter, R. M., P. J. Polverini, D. A. Arenberg, A. Walz, G. Opdenakker, J. Van Damme, and S. L. Kunkel. 1995. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukocyte Biol. 57:752.
51. Sternlicht, M. D., and Z. Werb. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17:463.
52. Whiteside, T. L., and G. Parmiani. 1994. Tumor-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol. Immunother. 39:15.
53. Yoshino, I., T. Yano, M. Murata, T. Ishida, K. Sugimachi, G. Kimura, and K. Nomoto. 1992. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 52:775.
54. Roussel, E., M.-C. Gingras, E. A. Grimm, and J. A. Roth. 1995. High expression of adhesion molecules/activation markers with little interleukin-2, interferon γ, and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol. Immunother. 41:1.
55. Hartveit, F. 1998. Breast cancer: Poor short-term prognosis in cases with moderate lymphocytic infiltration at the tumor edge: A preliminary report. Oncol. Rep. 5:423.
56. Moy, P. M., E. C. Holmes, and S. H. Golub. 1985. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 45:57.
57. Kudoh, S., C. Redovan, P. Rayman, M. Edinger, R. R. Tubbs, A. Novick, J. H. Finke, and R. M. Bukowski. 1997. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J. Immunother. 20:479.
58. Miescher, S., T. L. Whiteside, S. Carrel, and V. Von Fliedner. 1986. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136:1899.
59. Dustin, M. L., and A. R. de Fougerolles. 2001. Reprogramming T cells: The role of extracellular matrix in coordination of T cell activation and migration. Curr. Opin. Immunol. 13:286.
60. Ibe, S., Z. Qin, T. Schûler, S. Preiss, and T. Blankenstein. 2001. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194:1549.
61. McCawley, L. J., and L. M. Matrisian. 2001. Tumor progression: Defining the soil round the tumor seed. Curr. Biol. 11:R25.
62. Tlsty, T. D. 2001. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11:97.
63. Bukowski, R. M., P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al. 1999. Interferon-γ and CXC chemokine induction by interleukin 12 in renal cell carcinoma. Clin. Cancer Res. 5:2780.
64. Hill, H. C., T. F. Conway, Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez. Tumor vaccination with interleukin-12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Co-induction of innate and adaptive anti-tumor immunity and cure of disseminated disease. Cancer Res. In press.